Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Viridian Therapeutics Inc.’s current trading price is -57.05% away from its 52-week high, while its distance from the 52-week low is -4.23%. The stock’s price range during this period has varied between $17.49 and $39.00. The company, active in the Healthcare sector, saw a trading volume of around 1.37 million for the day, considerably higher average daily volume of 0.75 million observed over the last three months.
Currently, the stock price of Viridian Therapeutics Inc. (VRDN) is $16.75. In the most recent trading session, the stock underwent a significant upswing, peaking at $17.73 after opening at $17.60. The stock touched a low of $16.40 before closing at $17.75.
The stock market performance of Viridian Therapeutics Inc. has been fairly unsteady. Over the last year, the company’s stock hit its highest at $39.00 on 01/25/23, while the lowest price during the same time frame was $17.49, recorded on 09/13/23.
How Financial Performance Impacts Market Capitalization
Viridian Therapeutics Inc. (VRDN) has experienced a quarterly decline of -36.89% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 753.58M and boasts a workforce of 86 employees.
Decoding Analysts’ Ratings for Viridian Therapeutics Inc.
As of right now, 15 analysts are rating Viridian Therapeutics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 22.58, with a change in price of -11.99. Similarly, Viridian Therapeutics Inc. recorded 705,931 in trading volume during the last 100 days, posting a change of -41.72%.
How VRDN’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for VRDN stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.03.
VRDN Stock Stochastic Average
As of today, the raw stochastic average of Viridian Therapeutics Inc. over the last 50 days is at 4.15%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 8.58%. Further, the company’s Stochastic %K and %D values for the last 20 days were 5.15% and 6.47%, respectively.
VRDN Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. This year’s metric has recorded a Price decrease of -42.66%. However, over the past six months, we’ve seen a stronger performance of -41.29%. The price of VRDN leaped by -15.45% over the last 30 days. And in the last five days, it has fallen by -11.61%.